The quantitative validation of non-endoscopic disease activity indices in ulcerative colitis
dc.contributor.author | Higgins, Peter D.R. | en_US |
dc.contributor.author | Leung, J. | en_US |
dc.contributor.author | Schwartz, M. | en_US |
dc.contributor.author | Mapili, John | en_US |
dc.contributor.author | Wren, Patricia A. | en_US |
dc.contributor.author | Zimmermann, Ellen M. | en_US |
dc.date.accessioned | 2010-06-01T21:19:33Z | |
dc.date.available | 2010-06-01T21:19:33Z | |
dc.date.issued | 2007-02 | en_US |
dc.identifier.citation | HIGGINS, P. D. R.; LEUNG, J.; SCHWARTZ, M.; MAPILI, J.; WREN, P. A.; ZIMMERMANN, E. M. (2007). "The quantitative validation of non-endoscopic disease activity indices in ulcerative colitis." Alimentary Pharmacology & Therapeutics 25(3): 333-342. <http://hdl.handle.net/2027.42/74394> | en_US |
dc.identifier.issn | 0269-2813 | en_US |
dc.identifier.issn | 1365-2036 | en_US |
dc.identifier.uri | https://hdl.handle.net/2027.42/74394 | |
dc.identifier.uri | http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=retrieve&db=pubmed&list_uids=17269991&dopt=citation | en_US |
dc.format.extent | 659170 bytes | |
dc.format.extent | 3109 bytes | |
dc.format.mimetype | application/pdf | |
dc.format.mimetype | text/plain | |
dc.publisher | Blackwell Publishing Ltd | en_US |
dc.rights | 2007 The Authors Journal compilation 2007 Blackwell Publishing Ltd | en_US |
dc.title | The quantitative validation of non-endoscopic disease activity indices in ulcerative colitis | en_US |
dc.type | Article | en_US |
dc.subject.hlbsecondlevel | Otolaryngology | en_US |
dc.subject.hlbsecondlevel | Pharmacy and Pharmacology | en_US |
dc.subject.hlbtoplevel | Health Sciences | en_US |
dc.description.peerreviewed | Peer Reviewed | en_US |
dc.contributor.affiliationum | * Department of Internal Medicine, University of Michigan, Ann Arbor, MI | en_US |
dc.contributor.affiliationum | ¶ Department of Health Behavior and Health Education, University of Michigan, School of Public Health, Ann Arbor, MI, USA | en_US |
dc.contributor.affiliationother | † Department of Internal Medicine, University of Iowa, Iowa; | en_US |
dc.contributor.affiliationother | † Department of Internal Medicine, University of Chicago, Chicago; | en_US |
dc.contributor.affiliationother | § Department of Family Medicine, Wayne State University, Detroit; | en_US |
dc.identifier.pmid | 17269991 | en_US |
dc.description.bitstreamurl | http://deepblue.lib.umich.edu/bitstream/2027.42/74394/1/j.1365-2036.2006.03205.x.pdf | |
dc.identifier.doi | 10.1111/j.1365-2036.2006.03205.x | en_US |
dc.identifier.source | Alimentary Pharmacology & Therapeutics | en_US |
dc.identifier.citedreference | Truelove SC, Witts LJ. Cortisone in ulcerative colitis; final report on a therapeutic trial. Br Med J 1955; 4947: 1041 – 8. | en_US |
dc.identifier.citedreference | Powell-Tuck J, Bown RL, Lennard-Jones JE. A comparison of oral prednisolone given as single or multiple daily doses for active proctocolitis. Scand J Gastroenterol 1978; 13: 833 – 7. | en_US |
dc.identifier.citedreference | Walmsley RS, Ayres RC, Pounder RE, Allan RN. A simple clinical colitis activity index. Gut 1998; 43: 29 – 32. | en_US |
dc.identifier.citedreference | Lichtiger S, Present DH, Kornbluth A, et al. Cyclosporine in severe ulcerative colitis refractory to steroid therapy. N Engl J Med 1994; 330: 1841 – 5. | en_US |
dc.identifier.citedreference | Seo M, Okada M, Yao T, Ueki M, Arima S, Okumura M. An index of disease activity in patients with ulcerative colitis. Am J Gastroenterol 1992; 87: 971 – 6. | en_US |
dc.identifier.citedreference | Azzolini F, Pagnini C, Camellini L, et al. Proposal of a new clinical index predictive of endoscopic severity in ulcerative colitis. Dig Dis Sci 2005; 50: 246 – 51. | en_US |
dc.identifier.citedreference | Schroeder KW, Tremaine WJ, Ilstrup DM. Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study. N Engl J Med 1987; 317: 1625 – 9. | en_US |
dc.identifier.citedreference | Sutherland LR, Martin F, Greer S, et al. 5-Aminosalicylic acid enema in the treatment of distal ulcerative colitis, proctosigmoiditis, and proctitis. Gastroenterology 1987; 92: 1894 – 8. | en_US |
dc.identifier.citedreference | Rutgeerts P, Sandborn WJ, Feagan BG, et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med 2005; 353: 2462 – 76. | en_US |
dc.identifier.citedreference | Higgins PD, Schwartz M, Mapili J, Krokos I, Leung J, Zimmermann EM. Patient defined dichotomous end points for remission and clinical improvement in ulcerative colitis. Gut 2005; 54: 782 – 8. | en_US |
dc.identifier.citedreference | Higgins PD, Schwartz M, Mapili J, Zimmermann EM. Is endoscopy necessary for the measurement of disease activity in ulcerative colitis ? Am J Gastroenterol 2005; 100: 355 – 61. | en_US |
dc.identifier.citedreference | Irvine EJ. Quality of life – rationale and methods for developing a disease-specific instrument for inflammatory bowel disease. Scand J Gastroenterol Suppl 1993; 199: 22 – 7. | en_US |
dc.identifier.citedreference | Guyatt G, Mitchell A, Irvine EJ, et al. A new measure of health status for clinical trials in inflammatory bowel disease. Gastroenterology 1989; 96: 804 – 10. | en_US |
dc.identifier.citedreference | Irvine EJ, Feagan B, Rochon J, et al. Quality of life: a valid and reliable measure of therapeutic efficacy in the treatment of inflammatory bowel disease. Canadian Crohn's Relapse Prevention Trial Study Group. Gastroenterology 1994; 106: 287 – 96. | en_US |
dc.identifier.citedreference | Pallis AG, Mouzas IA, Vlachonikolis IG. The inflammatory bowel disease questionnaire: a review of its national validation studies. Inflamm Bowel Dis 2004; 10: 261 – 9. | en_US |
dc.identifier.citedreference | Jowett SL, Seal CJ, Phillips E, Gregory W, Barton JR, Welfare MR. Defining relapse of ulcerative colitis using a symptom-based activity index. Scand J Gastroenterol 2003; 38: 164 – 71. | en_US |
dc.identifier.citedreference | Vermeire S, Assche GV, Rutgeerts P. The role of C-reactive protein as an inflammatory marker in gastrointestinal diseases. Nat Clin Pract Gastroenterol Hepatol 2005; 2: 580 – 6. | en_US |
dc.identifier.citedreference | Solem CA, Loftus EV Jr, Tremaine WJ, Harmsen WS, Zinsmeister AR, Sandborn WJ. Correlation of C-reactive protein with clinical, endoscopic, histologic, and radiographic activity in inflammatory bowel disease. Inflamm Bowel Dis 2005; 11: 707 – 12. | en_US |
dc.identifier.citedreference | Vermeire S, Van Assche G, Rutgeerts P. C-reactive protein as a marker for inflammatory bowel disease. Inflamm Bowel Dis 2004; 10: 661 – 5. | en_US |
dc.identifier.citedreference | Kane SV, Sandborn WJ, Rufo PA, et al. Fecal lactoferrin is a sensitive and specific marker in identifying intestinal inflammation. Am J Gastroenterol 2003; 98: 1309 – 14. | en_US |
dc.identifier.citedreference | Sugi K, Saitoh O, Hirata I, Katsu K. Fecal lactoferrin as a marker for disease activity in inflammatory bowel disease: comparison with other neutrophil-derived proteins. Am J Gastroenterol 1996; 91: 927 – 34. | en_US |
dc.identifier.citedreference | Seo M, Okada M, Maeda K, Oh K. Correlation between endoscopic severity and the clinical activity index in ulcerative colitis. Am J Gastroenterol 1998; 93: 2124 – 9. | en_US |
dc.identifier.citedreference | Seo M, Okada M, Yao T, Okabe N, Maeda K, Oh K. Evaluation of disease activity in patients with moderately active ulcerative colitis: comparisons between a new activity index and Truelove and Witts’ classification. Am J Gastroenterol 1995; 90: 1759 – 63. | en_US |
dc.identifier.citedreference | Seo M, Okada M, Yao T, Matake H, Maeda K. Evaluation of the clinical course of acute attacks in patients with ulcerative colitis through the use of an activity index. J Gastroenterol 2002; 37: 29 – 34. | en_US |
dc.owningcollname | Interdisciplinary and Peer-Reviewed |
Files in this item
Remediation of Harmful Language
The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.
Accessibility
If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.